To test the potential of the new STK33 inhibitor Z29077885 as a therapeutic, we first selected breast cancer cell lines in which the function of STK33 is well understood, next generated three-dimensional (3D) breast cancer spheroids known to mimic cancer physiology [26, 27] and treated them with the drug for 72 h. The gene discussed is STK33; the disease is cancer.